Recent Updates
Recently added Catalysts

Sildenafil

Phase 1

Sexual Arousal Disorder | Small molecule | Psychiatry |Dare Bioscience, Inc.|Last Updated: Sep 4, 2025

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment13

FDA Designations

No designations recorded

Clinical trial landscape

Sildenafil · 1 trial · 1 indication

Phase 1 1
NCT05765487Using Thermography to Assess the Affects of Sildenafil Cream, 3.6%Sexual Arousal Disorder
COMPLETED13 Analytics
PHASE1COMPLETED
Using Thermography to Assess the Affects of Sildenafil Cream, 3.6%
Sexual Arousal DisorderUnlock trial analytics

Study Endpoints

Primary Endpoints

Evaluate the difference in vulvar blood flow after the use of investigational products
14 days

To evaluate and compare the impact of 2 grams of Sildenafil Cream 3.6%, Placebo Cream and Vehicle Cream on vulvar blood flow, as assessed by thermography in normal healthy premenopausal women.

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelCROSSOVER
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Sildenafil Cream, 3.6%ACTIVE_COMPARATORContains both Sildenafil and L-arginine
Placebo CreamPLACEBO_COMPARATORContains L-arginine, no Sildenafil
Vehicle CreamOTHERContains no L-arginine, no Sildenafil

Interventions

NameTypeDescription
SildenafilDRUGSildenafil Cream, 3.6%
VehicleDRUGNo Active or experimental ingredients
PlaceboDRUGCream with only L-arginine
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexFEMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Subject must be a premenopausal woman at least 18 years of age. * Subject must be willing to avoid high protein meals and follow dietary guidance provided by the study site staff for the duration of the study. * Women of childbearing potential must be using an acceptable form ...

Countries:Canada
Unlock Eligibility Criteria